These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16325821)

  • 1. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis.
    Schoppet M; Sattler AM; Schaefer JR; Hofbauer LC
    Atherosclerosis; 2006 Feb; 184(2):446-7. PubMed ID: 16325821
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
    Shin JY; Shin YG; Chung CH
    Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
    Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
    Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteoprotegerin (OPG)].
    Takahashi N; Kimura H; Yoshida H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():818-20. PubMed ID: 16149650
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG].
    Sasaki N; Kusano E
    Clin Calcium; 2006 Jun; 16(6):956-62. PubMed ID: 16751691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
    Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F
    Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma.
    Depil S; Mathiot C; Leleu X; Moreau AS; Faucompré JL; Hennache B; Bauters F; Bataille R; Facon T
    Br J Haematol; 2005 Jun; 129(5):706-7. PubMed ID: 15916694
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
    Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
    Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
    Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
    Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
    Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
    Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
    Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.